- Key leader in a cross-site, interdisciplinary team dedicated to targeted and target-agnostic screening approaches and target identification/validation serving multiple disease areas across the organization- Lead of the development and operationalization of a novel end-to-end platform for performing high throughput mRNA transcriptomics for profiling perturbagen signatures and biomarker strategies- Driving the development, validation, and execution of new technologies and models for cell-based screens andcompound profiling across complex assay systems and multiple modulator modalities for diverse therapeutic indications

Project leader (biology) for sphingosine-1-phosphate receptor lead optimization drug discovery campaign- Lead pre-clinical neuropathic pain drug discovery program from discovery phase to clinical candidate selection stage - Integrated internal and external in vitro pharmacology, in vivo pharmacology, pharmacokinetic and chemistry efforts to develop a first-in-class pain therapeutic targeting a novel G protein coupled receptor pharmacological profile-Discovered novel mechanism of compound differentiation that translates from cell culture to rodent and monkey- Served as Biological Safety Officer

Laboratory of Dr. Sandra Schmid- Investigating the crosstalk between agonist-promoted intracellular signaling and clathrin-coated pit dynamics using quantitative total internal reflection (TIRF) microscopy-based phenotypic screening